A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients

被引:48
作者
Raffi, F
Aboulker, JP
Michelet, C
Reliquet, V
Pelloux, H
Huart, A
PoizotMartin, I
Morlat, P
Dupas, B
Mussini, JM
Leport, C
Allegre, T
Aubertin, J
Beylot, J
Canton, P
AmbroiseThomas, P
Micoud, M
Peyramond, D
Trepo, C
Gastaut, JA
Janbon, F
Barrier, JH
Litoux, P
Dellamonica, P
Carbon, C
Coulaud, JP
Vachon, F
Vilde, JL
Sicard, D
Compagnucci, A
Marsal, L
Modai, J
Seligmann, M
Lang, JM
Lafeuillade, A
机构
[1] INSERM SC10,VILLEJUIF,FRANCE
[2] UNIV HOSP,DEPT INFECT DIS,RENNES,FRANCE
[3] UNIV HOSP,DEPT PARASITOL & MYCOL,GRENOBLE,FRANCE
[4] UNIV HOSP,DEPT HAEMATOL,MARSEILLE,FRANCE
[5] UNIV HOSP,DEPT INFECT DIS,BORDEAUX,FRANCE
[6] UNIV HOSP,DEPT RADIOL,NANTES,FRANCE
[7] UNIV PARIS,HOSP BICHAT CLAUDE BERNARD,PARIS,FRANCE
关键词
toxoplasmic encephalitis; AIDS; CT brain scan; prophylaxis; Toxoplasma serology; logistical model; empirical therapy;
D O I
10.1097/00002030-199702000-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To define the factors associated with diagnosis of toxoplasmic encephalitis (TE) in AIDS patients; and to establish a rational procedure for the clinician faced with a decision concerning empiric antitoxoplasma therapy. Design: A 15-month prospective multicentre cohort study in France. Methods: One hundred and eighty-six consecutive HIV-positive inpatients undergoing empiric antitoxoplasma therapy for a first episode of presumed TE were monitored. The clinician's initial estimation of the probability of response to antitoxoplasma therapy was recorded. In addition, a validation committee classified cases as TE or non-TE. Results: Among the 186 patients, the following variables were significantly more frequent in TE (n = 113)than non-TE (n = 73) patients: fever (59% versus 40%), headache (55% versus 33%), seizures (22% versus 11%), suggestive lesions on the brain scan (98% versus 76%), positive Toxoplasma serology (97% Versus 71%). Median CD4+ lymphocyte count was significantly higher in TE than in non-TE (27 x 10(6)/l versus 11 x 10(6)/l). The rate of TE in patients on systemic antiprotozoal prophylaxis at entry was 43% as compared with 75% in patients without previous prophylaxis. Pre-therapy estimation of response to empiric therapy was highly correlated with final diagnosis. Multivariate logistic regression analysis showed that the following variables contributed independently to the diagnosis of TE: clinician's estimation of response to treatment at entry > 75%; absence of systemic antiprotozoal prophylaxis; seizures; headache; suggestive lesions on CT or MRI brain scan; and positive Toxoplasma serology. Conclusions: A linear logistic model is proposed which uses significant variables, which are readily available. This model gives good accuracy to classify suspected cases of TE.
引用
收藏
页码:177 / 184
页数:8
相关论文
共 41 条
[21]   EFFICACY OF ATOVAQUONE IN TREATMENT OF TOXOPLASMOSIS IN PATIENTS WITH AIDS [J].
KOVACS, JA .
LANCET, 1992, 340 (8820) :637-638
[22]   Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: A double-blind, randomized trial [J].
Leport, C ;
Chene, G ;
Morlat, P ;
Luft, BJ ;
Rousseau, F ;
Pueyo, S ;
Hafner, R ;
Miro, J ;
Aubertin, J ;
Salamon, R ;
Vilde, JL ;
Blanc, AP ;
Schmitt, JL ;
Arlaud, J ;
Estavoyer, JM ;
Guillevin, L ;
Bentata, M ;
Beylot, J ;
Lacut, JY ;
Granier, P ;
Cosnard, F ;
Bazin, C ;
Dormont, J ;
Rey, M ;
Delaunay, C ;
Troisvallet, D ;
Micoud, M ;
Weinbreck, P ;
Trepo, C ;
Gallais, H ;
Gastaut, JA ;
Allard, C ;
Janbon, F ;
Canton, P ;
Grolleau, JY ;
Cassuto, J ;
Dellamonica, P ;
Duret, P ;
Frottier, J ;
Herson, S ;
Seligmann, M ;
Sereni, D ;
Giraudon, BB ;
Dien, G ;
Ruel, M ;
Storck, D ;
Jaubert, D ;
Lafeuillade, A ;
Mouton, Y ;
Choutet, P .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :91-97
[23]  
LEPORT C, 1992, PRESSE MED, V21, P1165
[24]   TREATMENT OF CENTRAL NERVOUS-SYSTEM TOXOPLASMOSIS WITH PYRIMETHAMINE SULFADIAZINE COMBINATION IN 35 PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME - EFFICACY OF LONG-TERM CONTINUOUS THERAPY [J].
LEPORT, C ;
RAFFI, F ;
MATHERON, S ;
KATLAMA, C ;
REGNIER, B ;
SAIMOT, AG ;
MARCHE, C ;
VEDRENNE, C ;
VILDE, JL .
AMERICAN JOURNAL OF MEDICINE, 1988, 84 (01) :94-100
[25]  
LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO
[26]  
2-G
[27]  
LEVY RM, 1986, AM J NEURORADIOL, V7, P833
[28]  
LEVY RM, 1990, J ACQ IMMUN DEF SYND, V3, P461
[29]  
LEVY RM, 1988, J ACQ IMMUN DEF SYND, V1, P41
[30]   TOXOPLASMIC ENCEPHALITIS IN AIDS [J].
LUFT, BJ ;
REMINGTON, JS .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (02) :211-222